Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1471-2407

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases ; volume:18 ; number:1 ; day:3 ; month:12 ; year:2018 ; pages:1-9 ; date:12.2018
BMC cancer ; 18, Heft 1 (3.12.2018), 1-9, 12.2018

Creator: Tan, Wan-Ling
Ng, Quan Sing
Lim, Cindy
Tan, Eng Huat
Toh, Chee Keong
Ang, Mei-Kim
Kanesvaran, Ravindran
Jain, Amit
Tan, Daniel S. W.
Lim, Darren Wan-Teck

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12885-018-5110-2

URN: urn:nbn:de:101:1-2019020611560877503497

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:45 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Tan, Wan-Ling
Ng, Quan Sing
Lim, Cindy
Tan, Eng Huat
Toh, Chee Keong
Ang, Mei-Kim
Kanesvaran, Ravindran
Jain, Amit
Tan, Daniel S. W.
Lim, Darren Wan-Teck
SpringerLink (Online service)

Other Objects (12)

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Afatinib in advanced NSCLC: a profile of its use

Afatinib (NSCLC mit Plattenepithelhistologie) : Nutzenbewertung gemäß § 35a SGB V

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence

Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis

Correction to: Afatinib in advanced NSCLC: a profile of its use

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Afatinib in advanced NSCLC: a profile of its use

Afatinib (NSCLC mit Plattenepithelhistologie) : Nutzenbewertung gemäß § 35a SGB V

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence

Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis

Correction to: Afatinib in advanced NSCLC: a profile of its use

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Afatinib in advanced NSCLC: a profile of its use

Afatinib (NSCLC mit Plattenepithelhistologie) : Nutzenbewertung gemäß § 35a SGB V

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence

Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis

Correction to: Afatinib in advanced NSCLC: a profile of its use

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Afatinib in advanced NSCLC: a profile of its use

Afatinib (NSCLC mit Plattenepithelhistologie) : Nutzenbewertung gemäß § 35a SGB V

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence

Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis

Correction to: Afatinib in advanced NSCLC: a profile of its use

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Afatinib in advanced NSCLC: a profile of its use

Afatinib (NSCLC mit Plattenepithelhistologie) : Nutzenbewertung gemäß § 35a SGB V

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence

Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis

Correction to: Afatinib in advanced NSCLC: a profile of its use

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Afatinib in advanced NSCLC: a profile of its use

Afatinib (NSCLC mit Plattenepithelhistologie) : Nutzenbewertung gemäß § 35a SGB V

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence

Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis

Correction to: Afatinib in advanced NSCLC: a profile of its use

Related objects

Reset password